CD274 and non-small cell lung carcinoma: In the ‘OAK’ study that enrolled patients with NSCLC, regardless of their PD-L1 status, median OS was 13.8 months in atezolizumab treated patients, which was 4.2 months longer than those treated with docetaxel chemotherapy.